As a result of increased glycosuria and natriuresis, the beneficial effects of SGLT2 inhibitors extend beyond glycemic control to reducing intraglomerular hypertension, promoting plasma volume contraction, lowering blood pressure (BP), reducing body weight, and decreasing uric acid levels4,5. This evidence concerns the gene SLC5A2 and hypertensive disorder.